Compare TGT & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TGT | ZTS |
|---|---|---|
| Founded | 1902 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.5B | 48.7B |
| IPO Year | 1994 | 2012 |
| Metric | TGT | ZTS |
|---|---|---|
| Price | $119.37 | $113.51 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 27 | 11 |
| Target Price | $118.60 | ★ $156.20 |
| AVG Volume (30 Days) | ★ 5.1M | 3.5M |
| Earning Date | 03-03-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.81% | 1.87% |
| EPS Growth | N/A | ★ 10.05 |
| EPS | ★ 8.13 | 6.02 |
| Revenue | ★ $72,618,000,000.00 | $9,467,000,000.00 |
| Revenue This Year | $2.90 | $5.67 |
| Revenue Next Year | $2.65 | $4.85 |
| P/E Ratio | ★ $14.71 | $18.84 |
| Revenue Growth | 1.88 | ★ 2.28 |
| 52 Week Low | $83.44 | $113.30 |
| 52 Week High | $126.00 | $172.23 |
| Indicator | TGT | ZTS |
|---|---|---|
| Relative Strength Index (RSI) | 59.99 | 34.32 |
| Support Level | $111.90 | N/A |
| Resistance Level | $126.00 | $130.52 |
| Average True Range (ATR) | 2.68 | 3.24 |
| MACD | -0.19 | -0.29 |
| Stochastic Oscillator | 69.43 | 1.81 |
Target's start dates back to 1962, but now it is one of the largest discount retailers in the United States (where it derives all of its sales), operating just under 2,000 stores and generating over $106 billion in fiscal 2024 sales. The company offers a broad assortment of merchandise across categories including apparel and accessories (16% of fiscal 2024 revenue), beauty and household essentials (30%), food and beverage (23%), hardlines (15%), as well as home furnishings (16%). Target's model is anchored in its physical store base, which fulfills more than 97% of sales. Around 30% of sales are derived from its own private-label brands.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its USA business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.